ORIC Pharmaceuticals, Inc. (ORIC) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
ORIC Pharmaceuticals, Inc.
Address
240 East Grand Avenue
South San Francisco, CA 94080
United States of America (the)
Phone
650 388 5600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
111
First IPO Date
April 24, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Jacob Chacko | President, Chief Executive Officer & Director | 1.11M | 1979 |
| Richard A. Heyman | Founder, Independent Chairman & Member of Scientific Advisory Board | 100,000 | 1957 |
| Dominic G. Piscitelli | Chief Financial Officer | 729,921 | 1975 |
| Pratik S. Multani | Chief Medical Officer | 774,937 | 1967 |
| Scott W. Lowe | Founder & Member of Scientific Advisory Board | 0 | N/A |
| Edna Chow Maneval | Executive Vice President of Clinical Development | 0 | 1961 |
| Kevin Brodbeck | Chief Technical Officer | 0 | N/A |
| Daniel Iazzetti | Vice President & Head of People | 0 | N/A |
| Christian V. Kuhlen | General Counsel | 0 | 1973 |
| Charles L. Sawyers | Founder & Member of Scientific Advisory Board | 0 | 1959 |
| Lori Sickels Friedman | Chief Scientific Officer | 0 | 1965 |
Description
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
